Infectious Disease

Because influenza outbreaks follow a humidity‑temperature curve, climate change may shift flu epidemics and reshape risk from tropics to temperate regions.

Messenger RNA vaccines were effective against any documented SARS-CoV-2 infection, against hospitalization, and against mortality within 14 to 42 days of vaccination.

COVID-19 boosters can also neutralize certain bat and pangolin coronaviruses, while immune "imprinting" from a person's first viral exposure limits how well that protection adapts to newer variants.

This FAQ outlines current measles cases, key drivers of increasing cases, and the essential role pharmacists play in vaccination, patient counseling, case recognition, and combating vaccine misinformation.

Pharmacists should be up-to-date on current outbreak status, US risk level, and how to recognize warning signs and counsel concerned patients as confirmed Ebola cases caused by Bundibugyo ebolavirus continue to rise across the Democratic Republic of the Congo (DRC) and Uganda.

With this approval, Capvaxive is the only PCV specifically indicated and studied in the US for use in this patient population.

The indication is for complicated urinary tract infections (UTIs) caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options.

Temperature differences between exhaled air and ambient environments significantly affect how respiratory aerosols disperse.

The inaugural Joint MAD-ID/SIDP Annual Meeting was a celebration of learning and networking and focused on the educational needs of infectious diseases pharmacist specialists.

New household data show recent COVID-19 shots cut at-home spread by 43%, strengthening pharmacist counseling on staying up to date.

Bundibugyo Ebola spreads in DRC and Uganda as the WHO declares a public health emergency of international concern; learn the case counts, travel alerts, and pharmacist readiness steps.

Spencer Durham, PharmD, FCCP, BCPS, BCIDP, discusses why hepatitis B remains an active public health threat.

The approval ends a decades-long gap in care for patients with chronic hepatitis delta virus (HDV) infection, a serious and life-threatening coinfection with hepatitis B that can rapidly progress to cirrhosis, liver cancer, and liver failure.

A large prospective cohort study offers pharmacists and clinicians new data to consider when counseling patients on the long-term value of early antiviral treatment.

Ashlan Kunz Coyne, PharmD, MPH, discusses treating Pseudomonas–Stenotrophomonas coinfections, co-culture insights, and smart empiric therapy amid rising resistance.

Pharmacists push antimicrobial stewardship into clinics and long-term care, tackling antifungal resistance, rapid diagnostics, vaccines, and public health leadership.

Recent randomized trials and CDC guidance support doxycycline postexposure prophylaxis as a targeted strategy to reduce bacterial STIs in high-risk populations.

Hirsch shows how mentorship and networks shape a pharmacist-scientist, driving infectious disease research and fosfomycin breakthroughs.

New findings reveal that mouse liver cells can form the viral template behind chronic HBV infection.

Ivermectin, vitamin D, and zinc are being recommended on social media as treatment for hantavirus—despite a lack of evidence.

A new study describes the high symptom burden carried by pediatric long COVID patients and highlights integrative medicine's role in their care.

The World Health Organization confirmed the outbreak is the Andes strain, the only known human transmissible hantavirus.

FDA leaders reportedly delay vaccine safety findings on COVID-19 and shingles shots, raising transparency concerns and new challenges for pharmacists.

A hantavirus outbreak aboard a cruise ship is raising urgent concerns about the dangers of this rare but deadly rodent-borne virus.

New trials show Pfizer’s Paxlovid (nirmatrelvir-ritonavir) speeds COVID-19 recovery in vaccinated patients, while hospitalization benefits fade.